What does the ASPECTS score determine, and why does it matter for treatment decisions?

The Alberta Stroke Program Early CT Score (ASPECTS) is a 10-point scale that quantifies early ischemic changes across 10 defined regions of the MCA territory on non-contrast CT. A score of 10 indicates no ischemic changes; a score of 0 indicates involvement of all 10 regions. Current stroke guidelines recommend mechanical thrombectomy for patients with ASPECTS of 6 or above, and the score also informs IV thrombolysis eligibility. A one-point difference can determine whether a patient receives intervention.

How does CINA-ASPECTS reduce inter-reader variability?

ASPECTS scoring on non-contrast CT is inherently subjective. Early ischemic changes - subtle hypodensity and sulcal effacement - are difficult to detect consistently, and published data shows significant disagreement between readers, particularly between less experienced and senior radiologists. CINA-ASPECTS applies the same algorithm to every scan, producing a standardized score and a region-by-region heat map that is independent of reader fatigue, experience level, or time of day.

What does CINA-ASPECTS deliver beyond the numerical score?

In addition to the ASPECTS score, CINA-ASPECTS provides three visual outputs: a heat map showing the probability of hypodensity or sulcal effacement across each of the 10 MCA territory regions; an outline of the areas identified as infarcted; and a reoriented and resliced NCCT to support consistent anatomical review. These outputs give the radiologist spatial context for the score, supporting faster and more confident reporting in a time-critical stroke workflow.

PRODUCT MANAGEMENT

Product Engineer
AI Medical Imaging

Full-Time

LA CIOTAT, FRANCE

ON SITE

The role

Reporting to the VP of Product, you own the full lifecycle of one or more software products. Your mission isn’t to ship features, it’s to make sure customers buy, deploy, and renew. Clinical and economic value is at the center of everything you do.

Value proposition

Define and prove why a healthcare institution buys and keeps each product. Identify the economic buyer, their pain points and the return they get.

Evidence & Usage Data

Instrument and document value with clinical and real-world data that sustains the commercial promise and defends the product over time.

Product Specifications

Gather field requirements, prioritize features with R&D based on contribution to adoption and sales, within the regulatory framework.

Positioning & Sales Enablement

Build buyer-centric personas, quantified value arguments, and materials that help sales close. Mobilize KOLs as credibility sources.

Value Loop

Analyze real-world usage, adoption, and renewal patterns; feed backlog priorities accordingly.

Development Tracking

Day-to-day R&D collaboration, product rituals, and deliverable validation.

What we're looking for

At least 3 years of product management experience in medtech or healthtech, on products that have been sold and deployed, not just specified.
Strong commercial sensibility: comfortable with ROI reasoning, health economics, and the institutional buying decision.
Solid clinical grounding in imaging, or a demonstrated ability to get up to speed quickly.
Ability to move between analytical mode (market, data, quantified value) and narrative mode (positioning, pitch).
Understanding of the SaMD regulatory framework (MDR, FDA) as a design constraint, not a side topic.
Fluent English required (US market and clinical contacts, international partners).

What we offer

A product with real clinical impact, in a market that's actively structuring itself, with broad and direct ownership.
Direct access to founders, R&D, and clinical advisors.
A structured product team with an engaged VP of Product.
Based in La Ciotat, with the option to work remotely up to two days per week.

Product Engineer AI Medical Imaging